Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesInsensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesStoichiometry of antibody neutralization of human immunodeficiency virus type 1.HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Dissection of antibody specificities induced by yellow fever vaccinationImproving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.A critical question for HIV vaccine development: which antibodies to induce?HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines.Multiantibody strategies for HIV.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsDesign, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.Synergy determination issues.Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses.
P2860
Q24561905-FAAEF16B-9F93-4B1D-BFED-B8F21E27CD81Q28469023-1E96CD63-6A18-4B26-96DC-1FD57F3C05EDQ29619015-71BB2D67-6CE2-4FB6-839E-387543A0072CQ33737656-47E5E9D7-6991-4980-AA6E-898EF0DACE0BQ33900395-BDC625E4-11F5-4520-ACD0-3219DCB5A582Q33939405-5FF039B9-173F-4DCF-9F9A-5624D01EE901Q34204047-DFFC863F-F95D-4EA5-94B8-57B30DC8921FQ34789343-5447AD99-AD8B-4827-B853-4574D9E21F0CQ35076711-644708A5-3650-4E26-AAEF-8CA2BBE855D0Q35155451-2ACD1B01-8D3D-49B5-BB51-4F99BF403484Q35540731-A9DD3FF8-301D-47FF-AE76-2F5A59B48B34Q35706462-5293435C-7300-4824-A2AE-5732A26671A2Q35783015-6B76BBDA-91E4-406E-8ADE-693A5587ECD8Q35826271-DB7AA8AA-FCE9-4817-987D-3EDA4785D67AQ36404194-8EADBBB6-0265-4224-AAF1-791963CF2EE1Q36715717-B0D3A67A-AAE8-4B5E-89AE-FCFDF1FAD602Q37208841-BB38E248-8400-43E2-86EC-7B75FF8F06CAQ38120526-B0504419-879E-49D1-AA9B-F8D13CD2F485Q38128299-8E9B3D73-B256-4DF6-92F5-703592C040EFQ39454698-1AE51BA2-0C09-4892-98C2-E1FAD1BFC283Q40430180-17F18E80-832B-45C5-BA49-857450E3C7BEQ41911898-EA052772-1E14-480B-9CF3-BC94DDA82509Q42572387-F11BDA2E-D6B3-438B-81D4-5E6CFF20D9EBQ42810005-8F4BC543-B4D6-443D-9C4D-BBD408196672Q52692047-EF642086-6EF0-4B70-8F14-F00B06D3A48D
P2860
Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@ast
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@en
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@nl
type
label
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@ast
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@en
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@nl
prefLabel
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@ast
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@en
Additive Effects Characterize ...... ency Virus Type 1 Isolate 89.6
@nl
P2093
P2860
P1433
P1476
Additive effects characterize ...... ncy virus type 1 isolate 89.6.
@en
P2093
S Zolla-Pazner
P2860
P304
P356
10.1128/JVI.75.19.9177-9186.2001
P577
2001-10-01T00:00:00Z